Minimal modeling approaches to value of information analysis for health research

Medical Decision Making

Volumn 31, Issue 6, 2011, Pages

  Meltzer, David O ^a,b   Hoomans, Ties ^a   Chung, Jeanette W ^a   Basu, Anirban ^a  

^a Section of Hospital Medicine   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

cost effectiveness analysis; research priorities; value of information analysis; value of research

Indexed keywords

ARTICLE; HEALTH SERVICES RESEARCH; ORGANIZATION AND MANAGEMENT; THEORETICAL MODEL;

HEALTH SERVICES RESEARCH; MODELS, THEORETICAL;

EID: 80955125667     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X11412975     Document Type: Article

References (48)

1. Murphy KM, Topel RH Measuring the Gains from Medical Research: An Economic Approach. Murphy KM Topel RH, ed. Chicago: University of Chicago Press; 2003: 41-73.
2. Cheng Y, Berry DA. Optimal adaptive randomized designs for clinical trials. Biometrika. 2007; 94 (3). 673-89
3. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998; 18: S68-80
4. Eckermann S, Willan AR. Globally optimal trial design for local decision making. Health Econ. 2009; 18: 203-216
5. Meltzer D. Addressing uncertainty in medical cost-effectiveness analysis: implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research. J Health Econ. 2001; 20 (1). 109-29
6. Drummond MF, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care. 1991; 7 (4). 561-73
7. Meltzer DO, Basu A, Meltzer HY. Comparative effectiveness research for antipsychotic medications: how much is enough?. Health Aff. 2009; 8 (5). w794-808
8. Detsky AS. Using economic analysis to determine the resource consequences of choices made in planning clinical trials. J Chronic Dis. 1985; 38 (9). 753-65 (Pubitemid 16242735)
9. Willan AR. Optimal sample size determinations from an industry perspective based on the expected value of information. Clin Trials. 2008; 5 (6). 587-94
10. Janssen MP, Koffijberg H. Enhancing value of information analyses. Value Health. 2009; 12 (6). 935-41
11. Detsky AS. Using cost-effectiveness analysis to improve the efficiency of allocating funds to clinical trials. Stat Med. 1990; 9 (1-2). 173-84 (Pubitemid 20294378)
12. Townsend J, Buxton M, Harper G. Prioritisation of health technology assessment. The PATHS model: methods and case studies. Health Technol Assess. 2003; 7 (20). iii 1-82
13. Ramsey SD, Blough DK, Sullivan SD. A forensic evaluation of the National Emphysema Treatment Trial using the expected value of information approach. Med Care. 2008; 46 (5). 542-8
14. Girling AJ, Freeman G, Gordon JP, Poole-Wilson P, Scott DA, Lilford RJ. Modeling payback from research into the efficacy of left-ventricular assist devices as destination therapy. Int J Technol Assess Health Care. 2007; 23 (2). 269-7
15. Stevenson MD, Scope A, Sutcliffe PA. The cost-effectiveness of group cognitive behavioral therapy compared with routine primary care for women with postnatal depression in the UK. Value Health. 2010; 13 (5). 580-4
16. Omenn GS. Assessment of human cancer risk: challenges for alternative approaches. Toxicol Pathol. 2001; 29: 5-12
17. Willan AR, Pinto EM. The value of information and optimal clinical trial design. Stat Med. 2005; 24 (12). 1791-806 (Pubitemid 40872643)
18. Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ. 2007; 16 (2). 195-209 (Pubitemid 46206613)
19. Willan A, Kowgier M. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. Clin Trials. 2008; 5 (4). 289-300
20. Willan AR, Eckermann S. Optimal clinical trial design using value of information methods with imperfect implementation. Health Econ. 2010; 19 (5). 549-61
21. Willan AR. Clinical decision making and the expected value of information. Clin Trials. 2007; 4 (3). 279-85 (Pubitemid 47400539)
22. Barton GR, Briggs AH, Fenwick EA Value Health. 2008: 886-97.
23. Fenwick E, Marshall DA, Blackhouse G, et al. Assessing the impact of censoring of costs and effects on health-care decision-making: an example using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Value Health. 2008; 11 (3). 365-75 (Pubitemid 351712969)
24. Groot Koerkamp B, Nikken JJ, Oei EH, Stijnen T, Ginai AZ, Hunink MG. Value of information analysis used to determine the necessity of additional research: MR imaging in acute knee trauma as an example. Radiology. 2008; 246 (2). 420-5
25. Groot Koerkamp B, Spronk S, Stijnen S, Hunink MGM. Value of information analyses of economic randomized controlled trials: the treatment of intermittent claudication. Value Health. 2010; 13 (2). 242-50
26. Forbes C, Wilby J, Richardson G, Sculpher M, Mather L, Riemsma R. A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer. Health Technol Assess. 2002; 6 (23). 1-119
27. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. 2008. Available from: URL: http://www.nice.org. uk/aboutnice/howwework/devnicetech/technologyappraisalprocessguides/ guidetothemethodsoftechnologyappraisal.jsp.Accessed 2 December 2010.
28. Dutch Health Care Insurance Board (CVZ). Guidelines for Pharmacoeconomic Research, Updated Version. Available from: URL http://www.cvz.nl/binaries/live/ CVZ-Internet/hst-content/nl/documenten/rubriek+zorgpakket/cfh/ richtlijnen+farmacoeconomisch+onderzoek+-+engels.pdf.Accessed 2 December 2010.
29. Dutch Health Care Insurance Board (CVZ). Leidraad uitkomstenonderzoek 'ten behoeve van de beoordeling doelmatigheid intramurale geneesmiddelen' [in Dutch]. Available from: URL: http://www.cvz.nl/binaries/live/CVZ-Internet/hst- content/nl/documenten/rapporten/2008/rpt0812+leidraad+uitkomstenonderzoek.pdf. Accessed 2 December 2010.
30. Smith DH, Drummond MF, Johnston S, Gordon A. Economic evaluation of liposomal doxorubicin versus topotecan for recurrent ovarian cancer in the UK. Value Health. 2001; 4: 88
31. Skwarski K, MacNee W, Wraith PK, Sliwinski P, Zielinski J. Predictors of survival in patients with chronic obstructive pulmonary disease treated with long-term oxygen therapy. Chest. 1991; 100 (6). 1522-7
32. Honey KL, Bennett P, Morgan M. A brief psycho-educational group intervention for postnatal depression. Br J Clin Psychol. 2002; 41: 405-9 (Pubitemid 35439331)
33. Siegenthaler MP, Westaby S, Frazier OH, et al. Advanced heart failure: feasibility study of long-term continuous axial flow pump support. Eur Heart J. 2005; 26: 1031-8 (Pubitemid 40695034)
34. Hutton EK, Kaufman K, Hodnett E, et al. External cephalic version beginning at 34 weeks' gestation versus 37 weeks' gestation: a randomized multicenter trial. Am J Obstet Gynecol. 2003; 189 (1). 245-54 (Pubitemid 36886558)
35. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian trial with palliative endpoints. J Clin Oncol. 1996; 14: 1756-64 (Pubitemid 26185452)
36. Bloomfield DJ, Krahn MD, Neogi T, et al. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian trial with palliative endpoints. J Clin Oncol. 1998; 16: 2272-9 (Pubitemid 28265068)
37. Goeree R, O'Brien BJ, Blackhouse G, Marshall J, Briggs A, Lad R. Cost-effectiveness and cost-utility of long-term management strategies for heartburn. Value Health. 2002; 5: 312-28 (Pubitemid 36998744)
38. Nikken JJ, Oei EH, Ginai AZ, et al. Acute peripheral joint injury: cost and effectiveness of low-field-strength MR imaging: results of randomized controlled trial. Radiology. 2005; 236: 958-67 (Pubitemid 41170860)
39. Spronk S, Bosch J, den Hoed P, Veen HF, Pattynama PM, Hunink MG. Cost-effectiveness of endovascular revascularization compared to supervised hospital-based exercise training in patients with intermittent claudication: a randomized controlled trial. J Vasc Surg. 2008; 48: 1472-80
40. Chiba N, van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E BMJ. 2002: 1012-6.
41. Marple BF, Roberts CS, Frytak JR, et al. Azithromycin extended release vs amoxicillin/clavulanate: symptom resolution in acute sinusitis. Am J Otolaryngol. 2010 ; 31 (1). 1-8
42. Drug Topics Red Book. Montvale, NJ: Thomson Healthcare; 2010 :
43. Tolley G, Babcock L, Berger M, et al Univer-sity of Chicago; 1986.
44. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008 2007; 58: 71-96
45. Cascinu S, Graziano F, Catalano G. Chemotherapy for advanced pancreatic cancer: it may no longer be ignored. Ann Oncol. 1999; 10: 105-9 (Pubitemid 29090599)
46. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-6 (Pubitemid 46972777)
47. AltekruseSFKosaryCLKrapchoM, eds. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/ 1975-2007/, based on November2009SEER data submission, posted to the SEER web site, 2010.
48. Danese MD, Reyes C, Northridge K, Lubeck D, Lin CY, O'Connor P. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. Clin Ther. 2008; 30 (4). 775-84 (Pubitemid 351689042)